Literature DB >> 11918088

The expression of rho proteins decreases with human brain tumor progression: potential tumor markers.

Marie-Annick Forget1, Richard R Desrosiers, MaestroRolandaF Del, Robert Moumdjian, Daniel Shedid, France Berthelet, Richard Béliveau.   

Abstract

Astrocytic tumors are the most common human brain tumors. Establishment of tumor grade is a key determinant both in the choice of a therapeutic approach and in the prognosis. The diagnosis of astrocytic tumors is currently determined following histopathological analysis. The identification of molecular markers would offer a complementary tool for characterizing tumors with respect to their clinical behavior. In this study we determined the expression levels of 3 small GTP binding proteins (RhoA, RhoB and Rac1), of their inhibitor RhoGDI and of caveolin-1 in 24 human astrocytic tumors of grades I to IV. Our results demonstrated that the expression of RhoA and RhoB decreased significantly in all brain tumors studied and was inversely related with tumor of grade II to IV malignancy. The amount of caveolin-1 immunodetected was not significantly different from normal brain samples while the Rac1 expression level was diminished in astrocytic tumors of grades III and IV. Our finding that RhoA and RhoB expression levels are correlated to tumor malignancy suggests that they may serve as novel and efficient diagnostic markers for astrocytic brain tumors of histological grade II to IV and complement currently applied histopathological analysis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11918088     DOI: 10.1023/a:1013884426692

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  35 in total

Review 1.  Caveolins, liquid-ordered domains, and signal transduction.

Authors:  E J Smart; G A Graf; M A McNiven; W C Sessa; J A Engelman; P E Scherer; T Okamoto; M P Lisanti
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

2.  Motility and invasion are differentially modulated by Rho family GTPases.

Authors:  J Banyard; B Anand-Apte; M Symons; B R Zetter
Journal:  Oncogene       Date:  2000-01-27       Impact factor: 9.867

Review 3.  Rho-like GTPases: their role in epithelial cell-cell adhesion and invasion.

Authors:  E E Sander; J G Collard
Journal:  Eur J Cancer       Date:  1999-09       Impact factor: 9.162

4.  Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1.

Authors:  W Zhang; B Razani; Y Altschuler; B Bouzahzah; K E Mostov; R G Pestell; M P Lisanti
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

5.  Caveolin isoforms differ in their N-terminal protein sequence and subcellular distribution. Identification and epitope mapping of an isoform-specific monoclonal antibody probe.

Authors:  P E Scherer; Z Tang; M Chun; M Sargiacomo; H F Lodish; M P Lisanti
Journal:  J Biol Chem       Date:  1995-07-07       Impact factor: 5.157

6.  Reduction of caveolin and caveolae in oncogenically transformed cells.

Authors:  A J Koleske; D Baltimore; M P Lisanti
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

7.  Rho proteins induce metastatic properties in vivo.

Authors:  L del Peso; R Hernández-Alcoceba; N Embade; A Carnero; P Esteve; C Paje; J C Lacal
Journal:  Oncogene       Date:  1997-12-18       Impact factor: 9.867

8.  Rho GTPases are over-expressed in human tumors.

Authors:  G Fritz; I Just; B Kaina
Journal:  Int J Cancer       Date:  1999-05-31       Impact factor: 7.396

9.  Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells.

Authors:  S W Lee; C L Reimer; P Oh; D B Campbell; J E Schnitzer
Journal:  Oncogene       Date:  1998-03       Impact factor: 9.867

10.  Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas.

Authors:  A Waha; A Baumann; H K Wolf; R Fimmers; J Neumann; D Kindermann; K Astrahantseff; I Blümcke; A von Deimling; U Schlegel
Journal:  J Neurosurg       Date:  1996-10       Impact factor: 5.115

View more
  37 in total

1.  RhoB deficiency in thymic medullary epithelium leads to early thymic atrophy.

Authors:  Arturo Bravo-Nuevo; Rebekah O'Donnell; Alexander Rosendahl; Jae Hoon Chung; Laura E Benjamin; Chikako Odaka
Journal:  Int Immunol       Date:  2011-08-23       Impact factor: 4.823

2.  The neddylation-cullin 2-RBX1 E3 ligase axis targets tumor suppressor RhoB for degradation in liver cancer.

Authors:  Junfeng Xu; Lihui Li; Guangyang Yu; Wantao Ying; Qiang Gao; Wenjuan Zhang; Xianyu Li; Chen Ding; Yanan Jiang; Dongping Wei; Shengzhong Duan; Qunying Lei; Peng Li; Tieliu Shi; Xiaohong Qian; Jun Qin; Lijun Jia
Journal:  Mol Cell Proteomics       Date:  2014-12-24       Impact factor: 5.911

Review 3.  Transcriptional and post-transcriptional regulation of the genes encoding the small GTPases RhoA, RhoB, and RhoC: implications for the pathogenesis of human diseases.

Authors:  Eirini Nomikou; Melina Livitsanou; Christos Stournaras; Dimitris Kardassis
Journal:  Cell Mol Life Sci       Date:  2018-03-02       Impact factor: 9.261

Review 4.  Changes in laminin isoforms associated with brain tumor invasion and angiogenesis.

Authors:  Julia Y Ljubimova; Manabu Fujita; Natalya M Khazenzon; Alexander V Ljubimov; Keith L Black
Journal:  Front Biosci       Date:  2006-01-01

5.  Resveratrol suppresses human glioblastoma cell migration and invasion via activation of RhoA/ROCK signaling pathway.

Authors:  Wei Xiong; Anan Yin; Xinggang Mao; Wei Zhang; Huiyong Huang; Xiang Zhang
Journal:  Oncol Lett       Date:  2015-11-06       Impact factor: 2.967

Review 6.  Caveolin-1, caveolae, and glioblastoma.

Authors:  Marie-Odile Parat; Gregory J Riggins
Journal:  Neuro Oncol       Date:  2012-04-16       Impact factor: 12.300

7.  Expression of KIAA 0864 protein in neuroepithelial tumors: an analysis based on the presence of monoclonal antibody HFB-16.

Authors:  Yasuo Sugita; Yasuhiro Nakamura; Munehiko Yamamoto; Sachiko Ogasawara; Kouichi Ohshima; Minoru Shigemori
Journal:  J Neurooncol       Date:  2008-05-06       Impact factor: 4.130

8.  ROCK I-mediated activation of NF-kappaB by RhoB.

Authors:  Pedro L Rodriguez; Sutapa Sahay; Oyenike O Olabisi; Ian P Whitehead
Journal:  Cell Signal       Date:  2007-08-08       Impact factor: 4.315

9.  Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth.

Authors:  Laura A Marlow; Lisa A Reynolds; Alan S Cleland; Simon J Cooper; Michelle L Gumz; Shinichi Kurakata; Kosaku Fujiwara; Ying Zhang; Thomas Sebo; Clive Grant; Bryan McIver; J Trad Wadsworth; Derek C Radisky; Robert C Smallridge; John A Copland
Journal:  Cancer Res       Date:  2009-02-10       Impact factor: 12.701

10.  Critical functions of RhoB in support of glioblastoma tumorigenesis.

Authors:  Yufang Ma; Yuanying Gong; Zhixiang Cheng; Sudan Loganathan; Crystal Kao; Jann N Sarkaria; Ty W Abel; Jialiang Wang
Journal:  Neuro Oncol       Date:  2014-09-12       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.